Neobe Therapeutics announces $2.34m financing for tumour research
Pioneer Group and 2048 Ventures backed the early-stage financing, alongside existing investors and an Innovate UK grant award.
Neobe Therapeutics announced a $2.34 million financing round on February 29, 2024, backed by new investors Pioneer Group and 2048 Ventures alongside Deep Science Ventures, Cancer Research Horizons and Discovery Park Ventures. The company also received a non-dilutive award through Innovate UK’s Future Economy Investor Partnership Programme.
The financing supports development of Neobe’s lead programme, including preclinical safety and efficacy studies, initial regulatory work and research team expansion. The company develops engineered microbes intended to alter the physical environment around solid tumours and improve access for immunotherapies.
Julie Wolf of 2048 Ventures and Imelda Juniarsih of Pioneer Group joined Neobe’s board as investor directors. The company was founded in 2021 through a venture creation alliance between Deep Science Ventures and Cancer Research Horizons.
Use of funds
Lead programme preclinical development
Safety and efficacy studies
Initial regulatory validation
Research team expansion
Funding history
Sources
- London-based Neobe raises €6.1 million to engineer bacteria that break down barriers protecting cancer tumourseu-startups.com · Nov 10, 2026
- Neobe Raises $6.8 Million to Break Down the Barriers That Stop Cancer Treatments From Workingbusinesswire.com · Nov 10, 2026
- Neobe Therapeutics raises over $2 million for synthetic biology-enabled tumour microenvironment remodellingbioindustry.org · Feb 29, 2024
- Our Investment in Neobe2048.vc · Feb 29, 2024